Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Head & Neck 5Thoracic 4Sarcoma 2Lymphoid 2Breast 2Gynecologic 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Neoplasm Metastasis 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × penpulimab × Endocrine × Clear all
NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Peking Union Medical College Hospital

Phase 2 Unknown
5 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡